Allos Therapeutics, Inc. (ALTH) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Allos Therapeutics, Inc. (ALTH)

An SI Board Since July 2002

Posts	SubjectMarks	Bans	Symbol
226	18	0	ALTH

Emcee: Arthur Radley	Type: Unmoderated

Introduction Market Data Compact

With the recent massacre of biotech stocks, it is surprising to find a biotech that is currently trading less than a $1.00 from its 52 week high. However, that is the case for Allos(ALTH).

Allos is a biotech that apparently has a nice cash position(approximately $72 million)and a drug in Phase III trials. Their closest competitor was (PCYC), but in recent trials their drug didn't meet the end point of the study, thus it leaves Allos in the driver's seat to address this critical cancer treatment need.

The following is information on this company and any discussion will be appreciated. I do hold a small position in the stock:

Cash, cash equivalents, short-term investments and long-term marketable securities as of June 30, 2002 were $73.6 million.

Second Quarter Highlights:

-- An independent Data Safety Monitoring Committee (DSMC) performed a
formal interim analysis for efficacy and recommended that the
Company's pivotal Phase 3 study of RSR13 (efaproxiral) for the
treatment of patients with brain metastases be continued. This also
represented the fourth time the DSMC had reviewed the data for safety.
Patient accrual during the second quarter was strong; as a result, the
Company now anticipates that it will complete enrollment in the third
quarter of 2002.

-- Phase 2 non-small cell lung cancer survival data was presented in a
poster presentation at the 38th Meeting of The American Society of
Clinical Oncology (ASCO). The updated study, with a median follow up
of 22.9 months, showed median survival results of 20.6 months. The
relevant comparison group for this study (LAMP ACR 427:Arm I) showed
13.0 months for the identical treatment regimen, minus RSR13.

-- Meetings were held with select EU regulatory agencies regarding the
submission of an MAA (Marketing Authorization Application) for the
approval of RSR13 for the treatment of brain metastases and to discuss
a planned Phase 3 trial of RSR13 for the treatment of non-small cell
lung cancer.

-- Michael D. Casey was elected to the Company's Board of Directors and
the Audit Committee of the Board of Directors. Mr. Casey recently
spent four years as president, chief executive officer and chairman of
Matrix Pharmaceutical, Inc. Before that, he spent 25 years with
Johnson & Johnson. The Company believes that Mr. Casey's background
and experience help guide the Company as it enters the
commercialization phase of the development of RSR13.

-- The Company completed a private placement of 2,500,000 shares of
common stock to Perseus-Soros BioPharmaceutical Fund, L.P. for
aggregate gross proceeds of $15 million. The proceeds will be used to
fund future clinical development and commercialization of RSR13 and
BGP-15, a compound that was in-licensed in March 2002.

-- The Company was added to the Russell 3000(R) Index of publicly traded
companies.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
226	Hmmmm.....and now it's around $2 a share. Perhaps someone can tell me what h	Chris08	-	6/21/2011
225	Good call, as it got pretty close to your target this April. Did you take some	tuck	-	7/20/2010
224	[t]ALTH[/t] has been basing nicely around $6, and in my opinion, is about to mov	Mike Maxton	-	12/19/2009
223	Allos Therapeutics Announces FDA Advisory Committee Recommends Accelerated Appro	kenhott	-	9/3/2009
222	It looks like the filed sale is in connection with a 10b5-1 plan, so maybe not s	idos	-	9/1/2009
221	FWIW insiders sold substantial amounts of shares earlier this month. Kind of sli	rkrw	-	8/28/2009
220	My bad. Briefing docs are already out: fda.gov Explains the wide swing in pri	tuck	-	8/28/2009
219	Briefing docs are already out, Sep 2nd, Onco. Adv. Cmt. Don't have a quick	kenhott	-	8/28/2009
218	So the PDUFA date for PDX in PTCL is 9/24/2009. Yet the OI in Allos options is	tuck	-	8/28/2009
217	Allos: 27% of Patients Respond to Pralatrexate Adam Feuerstein 12/07/08 - 05:3	Doc Bones	-	12/8/2008
216	Don't care for the reduction in RR?	keokalani'nui	-	5/16/2008
215	I am out. No joke about being out of my mind, etc.	kenhott	-	5/16/2008
214	Indication and need are the reasons for the trial design. Total enrollment over	kenhott	-	4/23/2008
213	I haven't followed this closely, but . . . it sure is a good thing th	tuck	-	4/22/2008
212	Allos Therapeutics Completes Patient Enrollment in Pivotal Phase 2 PROPEL Trial	kenhott	-	4/22/2008
211	Allos Therapeutics Initiates Phase 2b Study of PDX in Patients With Non-small Ce	kenhott	-	1/7/2008
210	I noticed that the posters were basically unreadable. Email Allos and they will	kenhott	-	12/12/2007
209	Great Post kenhott! Tell me some more	tronitup	-	12/11/2007
208	ALTH 8k 10/25/07 sec.gov On October 25, 2007, Allos Therapeutics, Inc.’s (the	kenhott	-	12/7/2007
207	Interim Response and Safety Analyses Support Continuation of Allos Therapeutics&	kenhott	-	9/26/2007
206	Allos article from MF (5-21-07) - >>> Allos Aligned for Success fool.c	gfp927	-	6/7/2007
205	alth going 9% down now in large vol and no news.	idos	-	9/14/2006
204	09:44 am Allos Therapeutics: Needham & Co upgrades Buy to Strong Buy. Target	Ian@SI	-	9/6/2006
203	Allos Therapeutics Receives Special Protocol Assessment for Pivotal Phase 2 Stud	LJM	-	8/2/2006
202	Here's the chart I was talking about, with just a few random holdings thrown	FiloF	-	7/27/2006

Go to reply# or date (mm/dd/yy):